| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/01/2004 | CA2808318A1 A set of oligo-nucleotides against hiv infection and its application in the prevention and treatment of acquired immune deficiency syndrome |
| 07/01/2004 | CA2808190A1 A set of oligo-nucleotides against hiv infection and its application in the prevention and treatment of acquired immune deficiency syndrome |
| 07/01/2004 | CA2511665A1 Endothelial cell specifically binding peptides |
| 07/01/2004 | CA2510150A1 Compounds and methods for detection of carcinomas and their precursor lesions |
| 07/01/2004 | CA2510143A1 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors |
| 07/01/2004 | CA2510049A1 Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom |
| 07/01/2004 | CA2509827A1 A set of oligo-nucleotides against hiv infection and its application in the prevention and treatment of acquired immune deficiency syndrome |
| 07/01/2004 | CA2509825A1 Antagonists for human prolactin |
| 07/01/2004 | CA2509817A1 Forming iron nitrosyl hemoglobin |
| 07/01/2004 | CA2509618A1 Pharmaceutical compositions for treating non-ischemic heart failure |
| 07/01/2004 | CA2509356A1 Glucose and/or fructose transporter naglt1 and its gene |
| 07/01/2004 | CA2509348A1 Peptides impairing pbx dependent gene regulation |
| 07/01/2004 | CA2509216A1 Pharmaceutical porous particles |
| 07/01/2004 | CA2509215A1 Method for identifying modulators of human orexin-2 receptor |
| 06/30/2004 | EP1433855A2 Plasmids suitable for il-2 expression |
| 06/30/2004 | EP1433849A1 NOVEL POLYPEPTIDE, DNA THEREOF AND USE OF THE SAME |
| 06/30/2004 | EP1433847A1 Method of interfering with gene expression in mammalian post-implantation embryos |
| 06/30/2004 | EP1433792A2 Human receptor proteins, related reagents and methods |
| 06/30/2004 | EP1433781A1 Pyrrolidine carboxylic acid derivatives |
| 06/30/2004 | EP1433525A1 Sensitive substance encapsulation |
| 06/30/2004 | EP1433485A2 A uro-genital condition treatment system |
| 06/30/2004 | EP1433484A1 Use of interleukin-18 for treating skin disorders associated with UV radiation |
| 06/30/2004 | EP1432824A2 Compositions and methods relating to prostate specific genes and proteins |
| 06/30/2004 | EP1432821A2 A method for the early detection of cancer |
| 06/30/2004 | EP1432803A2 Fragments of the human zn-alpha2-glycoprotein and their use in methods of treatment of obesity |
| 06/30/2004 | EP1432802A2 Pegylated and diglycosylated erythropoietin |
| 06/30/2004 | EP1432801A2 Receptors and membrane-associated proteins |
| 06/30/2004 | EP1432800A2 Novel nucleic acids and polypeptides |
| 06/30/2004 | EP1432799A2 Silencing of gene expression by sirna |
| 06/30/2004 | EP1432794A2 Human coagulation factor vii polypeptides |
| 06/30/2004 | EP1432790A1 Regulation of cytotrophoblast cell differentiation and cell migration |
| 06/30/2004 | EP1432738A1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| 06/30/2004 | EP1432736A2 METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l) |
| 06/30/2004 | EP1432733A2 Gene regulatory peptides |
| 06/30/2004 | EP1432732A2 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state |
| 06/30/2004 | EP1432730A2 Glucagon-like peptide-1 analogs |
| 06/30/2004 | EP1432729A2 Peyers's patch and/or m-cell targeting ligands |
| 06/30/2004 | EP1432728A2 Methods and compositions for treating inflammatory disorders |
| 06/30/2004 | EP1432726A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/30/2004 | EP1432725A1 RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/30/2004 | EP1432724A1 Rna interference mediated inhibition of map kinase genes |
| 06/30/2004 | EP1432723A2 Modulation of the expression of genes dependent on stat-1 |
| 06/30/2004 | EP1432711A1 1,6-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432710A1 1, 8-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432679A1 Preparation and use of pyrrole derivatives for treating obesity |
| 06/30/2004 | EP1432460A2 Bioactive materials for aneurysm repair |
| 06/30/2004 | EP1432454A2 Methods for sterilizing preparations containing albumin |
| 06/30/2004 | EP1432452A2 Inhibition of stat-1 |
| 06/30/2004 | EP1432447A2 Combined compositions and methods for tumor vasculature coagulation and treatment |
| 06/30/2004 | EP1432444A2 Anti-a-beta antibodies |
| 06/30/2004 | EP1432443A2 Angiotensin peptide-carrier conjugates and uses thereof |
| 06/30/2004 | EP1432441A2 Use of hmgb1 for the activation of dendritic cells |
| 06/30/2004 | EP1432438A2 Use of rank antagonists to treat cancer |
| 06/30/2004 | EP1432437A2 Human tissue urokinase type plasminogen activator formulation |
| 06/30/2004 | EP1432436A2 Nutrient therapy for immuno-compromised patients |
| 06/30/2004 | EP1432435A1 Enamel matrix protein compositions for modulating immune response |
| 06/30/2004 | EP1432434A2 Use of substances with oxytocin activity for the preparation of a pharmaceutical composition against inflammation |
| 06/30/2004 | EP1432433A2 Antagonists |
| 06/30/2004 | EP1432432A2 A cancer treatment system |
| 06/30/2004 | EP1432431A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 06/30/2004 | EP1432430A2 Pre-mixes of glp-1 and basal insulin |
| 06/30/2004 | EP1432426A2 USE OF UNMETHYLATED CpG |
| 06/30/2004 | EP1432418A1 Treatment of hepatitis b virus infection with human monoclonal antibodies |
| 06/30/2004 | EP1432407A1 Lisinopril compositions having large-particle dcpd |
| 06/30/2004 | EP1383380A4 Fizz1 for metabolism regulation |
| 06/30/2004 | EP1326851B1 Substituted dipeptides as growth hormone secretagogues |
| 06/30/2004 | EP1267916B1 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance |
| 06/30/2004 | EP1173413B1 Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors |
| 06/30/2004 | EP1150699A4 Treatment of bladder and gastrointestinal mastocytosis |
| 06/30/2004 | EP1121146B1 Utilization of proteolytic enzymes to influence hyperactive t cells |
| 06/30/2004 | EP1009421B1 Compositions for enhanced wound healing |
| 06/30/2004 | EP0862628B1 Receptor and nucleic acid molecule encoding said receptor |
| 06/30/2004 | EP0851876B1 Antisecretory factor peptides regulating pathological permeability changes |
| 06/30/2004 | EP0848756B1 Materials and methods relating to the attachment and display of substances on cell surfaces |
| 06/30/2004 | EP0815125B1 THE gC1q RECEPTOR, HIV-1 gp120 REGION BINDING THERETO, AND RELATED PEPTIDES AND TARGETING ANTIBODIES |
| 06/30/2004 | EP0726311B1 Process for preparing human activated protein c |
| 06/30/2004 | EP0690722B1 Composition and method for reducing toxicity of biologically-active factors |
| 06/30/2004 | EP0686161B1 Novel human beta2 integrin alpha subunit |
| 06/30/2004 | EP0584167B1 Recombinant dna coding for signal peptide, selective interacting polypeptide and membrane anchoring sequence |
| 06/30/2004 | EP0527788B1 Hepatitis c virus protease |
| 06/30/2004 | CN1509337A New polynucleotides and polypeptides of IFN alpha-17 gene |
| 06/30/2004 | CN1509333A Novel neurotrophic factors |
| 06/30/2004 | CN1509328A Use of opg ligand to modulate immune response |
| 06/30/2004 | CN1509294A High density lipoprotein-reactive peptides |
| 06/30/2004 | CN1509292A Combination apparoach to treatment of cancer using C-MYC antisense oligomer |
| 06/30/2004 | CN1508265A Interleukin-2 and tes method of its gene in drug-stopping application |
| 06/30/2004 | CN1508253A Hybrid expression of Neisseria protein |
| 06/30/2004 | CN1508154A Method for preparing injection collagen, and product and use thereof |
| 06/30/2004 | CN1508151A Gclq receptor, HIV-laplzo area jointed with same and relative peptide and target-directional antibody |
| 06/30/2004 | CN1508141A Nucleotide sequence for anti HIV infection and preventing AIDS and use thereof |
| 06/30/2004 | CN1155706C Method for treating amyotrophic lateral sclerosis |
| 06/30/2004 | CN1155618C PEG-interferon conjugates |
| 06/30/2004 | CN1155617C Novel peptides for use in treatment of t-cell mediated cartilage destruction in autoimmune diseases |
| 06/30/2004 | CN1155615C Human protein with cancer cell growth suppressing function and its coding sequence |
| 06/30/2004 | CN1155614C Human protein with cancer cell growth suppressing function and its coding sequence |
| 06/30/2004 | CN1155613C Human tumor associated gene in 1-zone 3-band 3-subband of short arm of human chromosome No. 17 and its coding protein |
| 06/30/2004 | CN1155612C Endothelin antagon |
| 06/30/2004 | CN1155611C Endothelin antagon |
| 06/30/2004 | CN1155408C Stable lyophilized pharmaceutical substance from monoclonal or polyclonal antibodies |
| 06/30/2004 | CN1155407C Method for preparing intestinal transmitted non-A and non-B hepatitis vaccine |